骨关节炎
软骨
透明质酸
炎症
触变性
体内
药物输送
材料科学
关节炎
生物医学工程
医学
纳米技术
病理
内科学
解剖
复合材料
替代医学
生物技术
生物
作者
Liling Mei,Hui Wang,Jintian Chen,Ziqian Zhang,Feng Li,Yecheng Xie,Ying Huang,Tingting Peng,Guohua Cheng,Xin Pan,Chuanbin Wu
出处
期刊:Biomaterials Science
[The Royal Society of Chemistry]
日期:2021-01-01
卷期号:9 (21): 7205-7218
被引量:12
摘要
Osteoarthritis (OA) is a chronic joint disease with occurrence of articular inflammation and cartilage degeneration. An ideal drug delivery system for effective treatment of OA should integrate inflammation alleviation with cartilage protection. Herein, a lyotropic liquid crystal (LLC) precursor co-loading hyaluronic acid (HA) and celecoxib, formulated as the HLC precursor, was developed for the combined therapeutic efficacy. The in situ gelling property of the HLC precursor effectively prolongs drug retention in the articular cavity to achieve a long-term anti-inflammation effect. Based on the rheological tests, HLC gel with a cubic lattice structure endows it with a spring-like effect to buffer joint shock and shows great potential in providing cartilage protection by resisting mechanical destruction, lubricating joint, and decomposing intensive stress (about 50%). Meanwhile, the pharmacodynamics study on the OA-induced SD rats demonstrated that HLC gel was the most effective to reduce inflammation levels and to protect the cartilage against abrasion and degeneration. Furthermore, the in vivo degradation behavior and the intra-articular irritation results of LLC/HLC gel demonstrated that it was biodegradable and biocompatible. These results collectively demonstrated that HLC gel with anti-inflammation and cartilage protection performance provides a useful approach to treat OA.
科研通智能强力驱动
Strongly Powered by AbleSci AI